Canadian Sec - Delayed Quote CAD

Izotropic Corporation (IZO.CN)

0.2950

+0.0150

+(5.36%)

At close: 3:58:11 PM EDT

Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 2, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has engaged an International Communications Consultant, and granted Incentive Stock Options and Restricted Share

Newsfile last month

IZOZF
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication

- FDA meeting facilitated positive collaborative exchange -- Key topics included the clinical study protocol synopsis, the benefits versus risks of contrast-enhancement, and the management of breast cancers found on IzoView Breast CT that are not visible on digital breast tomosynthesis -- Izotropic to submit meeting minutes to the FDA prior to more detailed disclosure -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - March 25, 2025) - Izotropic Corporation (CSE: IZO) (OT

Newsfile last month

IZOZF
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

GlobeNewswire last month

PDSB

TELIF

BPTSY
Life Sciences Investor Forum Agenda Announced for March 13th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4hnure6 It is recommended that inve

GlobeNewswire last month

NGENF

BPTSY

HMTXF
Izotropic to Present at Investor Conference March 13th

- CEO to discuss IzoView's competitive advantage, expansion strategy, and potential revenue models -- Event includes live Q and A, attendance is complimentary -- Individual and institutional investors, advisors, and analysts welcome -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - March 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovativ

Newsfile 2 months ago

IZOZF
FDA Sets Meeting Date with Izotropic

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that the U.S. Food and Drug Administration ("FDA") has set the Company's pre-submission meeting date, further to its

Newsfile 2 months ago

IZOZF
Izotropic Closes Non-Brokered Private Placement

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 14, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its February 7th announcement it has completed a non-brokered private placement financing (the "Offe

Newsfile 2 months ago

IZOZF
Izotropic Announces Non-Brokered Private Placement

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 7, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announced today that

Newsfile 3 months ago

IZOZF
Izotropic Reschedules Investor Conference Presentation to March 13th

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 5, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces it is rescheduling its attendance and presentation at the OTC's Virtual Investor Conference from Thursday February 6t

Newsfile 3 months ago

IZOZF
Small Cap Growth Virtual Investor Conference Agenda Announced for February 6th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Small Cap Growth Virtual Investor Conference to be held February 6th. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3PUIzQM It is recommended that investors pre-register and ru

GlobeNewswire 3 months ago

BTQQF

VRDR

IZOZF
Izotropic to Present at Investor Conference February 6th

- CEO to present overview of Company value proposition, unique catalysts, and near-term objectives - - Event includes live Q and A, attendance is complimentary - - Individual and institutional investors, advisors, and analysts welcome - VANCOUVER, British Columbia and SACRAMENTO, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative a

GlobeNewswire 3 months ago

IZOZF
Izotropic Announces Timelines and Milestones to IzoView Product Launch

- Unique dense breast tissue focus to drive expedited recruitment rates; modular clinical study design reduces time to PMA submission by ~6 months -- 3 Site U.S.-based clinical study enables early data collection to kickstart European CE Mark Application -- Company to announce development of 2 new medical imaging devices in the next 12 months to trigger momentum and increase valuation during clinical data collection phase -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. -

Newsfile 3 months ago

IZOZF
Izotropic Featured in Announcement of Research and Markets' U.S. Breast Cancer Analysis and Forecast

- Company listed in Research and Markets' announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - "U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"--Report supports Company's regulatory strategy for IzoView Breast CT, reinforces high demand for new ...

Newsfile 3 months ago

IZOZF
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions

-New FDA Consultant is the former Director of the Division of Imaging, Diagnostics, and Software Reliability at the U.S Food and Drug Administration--New Biostatistical Consultant is the former Deputy Director of the Biostatistics and Data Management Center of the American College of Radiology Imaging Network, an NIH-funded cooperative that conducts clinical trials to evaluate the use of diagnostic imaging and image-guided treatments for cancer, has decades of successful experience in design and

Newsfile 3 months ago

IZOZF
Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening

-A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView scans by over 800%1 for initial approval and product launch- -Regulatory strategy responds to the "urgent call2" from the U.S. Preventative Services Task Force for solutions to finding breast cancers earlier in women with dense breast tissue--Comprehensive filing includes patient acquisition and clinical study plans that validate a projected clinical study timeline

Newsfile 3 months ago

IZOZF
Izotropic Provides Update on Annual General Meeting Materials and Voting Procedures

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announces that due to the suspension of mail service in Canada due to the nationwide strike of the Canadian Union of Postal Workers, that the notice of meeting, information circular, requests for financial statements and proxy form (the "Meeting Mat

Newsfile 5 months ago

IZOZF
Izotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU

Vancouver, British Columbia--(Newsfile Corp. - August 23, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a breast CT (computed tomography) imaging system, is pleased to announce that it is pursuing a regulatory strategy in the U.S. and EU to launch IzoView as a diagnostic device indicated for use in patients with dense breast tissue, a normal variation associated with an increased risk for devel

Newsfile 8 months ago

IZOZF
Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") - Further to the Company's news release of June 6, 2024, the Company is pleased to announce that it has completed the first tranche of its non-brokered private placement financing (the "Offering"), whereby the Company issued 1,800,000 units (each, a "Unit") at a price of $0.10 per Unit for gross proceeds of $180,000.00. ...

Newsfile 10 months ago

IZOZF
Izotropic Corporation Announces Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announced today that it intends to complete a small non-brokered private placement financing (the "Offering") of up to 3,000,000 units of the Company, (each a "Unit") at a price of $0.10 per each Unit for a gross proceeds of up to $300,000.00. ...

Newsfile 10 months ago

IZOZF

Performance Overview

Return	IZO.CN	S&P/TSX Composite index (^GSPTSE)
YTD	+391.67%	+3.70%
1-Year	+145.83%	+14.45%
3-Year	-50.83%	+29.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Izotropic Corporation (IZO.CN)

Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender

Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for March 13th

Izotropic to Present at Investor Conference March 13th

FDA Sets Meeting Date with Izotropic

Izotropic Closes Non-Brokered Private Placement

Izotropic Announces Non-Brokered Private Placement

Izotropic Reschedules Investor Conference Presentation to March 13th

Small Cap Growth Virtual Investor Conference Agenda Announced for February 6th

Izotropic to Present at Investor Conference February 6th

Izotropic Announces Timelines and Milestones to IzoView Product Launch

Izotropic Featured in Announcement of Research and Markets' U.S. Breast Cancer Analysis and Forecast

Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions

Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening

Izotropic Provides Update on Annual General Meeting Materials and Voting Procedures

Izotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU

Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Izotropic Corporation Announces Non-Brokered Private Placement

Performance Overview